Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Astrazeneca Plc Ord
(OP:
AZNCF
)
174.90
UNCHANGED
Streaming Delayed Price
Updated: 1:32 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Astrazeneca Plc Ord
< Previous
1
2
3
4
5
6
7
8
Next >
AstraZeneca Pulls Plug On Ionis Pharma-Partnered Cholesterol Med
September 23, 2022
Via
Benzinga
With Upcoming Contentious Meeting, This Analyst Cuts Price Target On Spectrum Pharma
September 21, 2022
Via
Benzinga
AstraZeneca's Asthma Treatment Scores European Approval
September 21, 2022
Via
Benzinga
AstraZeneca's COVID-19 Antibody Treatment Scores Approval In Europe
September 20, 2022
Via
Benzinga
AstraZeneca's COVID-19 Antibody Cocktail, RSV Treatment For Infants Gets European Authority Backing
September 16, 2022
Via
Benzinga
AstraZeneca's Blood Clot Treatment Hits Primary Goal In Rare Blood Disorder Trial
September 16, 2022
Via
Benzinga
Top Financial Stories Tuesday, September 13: Elon Musk's Takeover Set To Get Twitter Shareholder Approval, Intel Slashes Mobileye IPO Valuation, Goldman Sachs To Layoff About 500 Jobs And More...
September 13, 2022
Wall Street Journal
Via
Benzinga
US Judge Dismisses Shareholder Lawsuit Over AstraZeneca's COVID-19 Vaccine Disclosures: Report
September 13, 2022
Via
Benzinga
AstraZeneca-Merck's Lynparza Treatment Shows Long-Term Survival In Ovarian Cancer
September 09, 2022
Via
Benzinga
AstraZeneca Imfinzi Combo Scores FDA Approval As First Immunotherapy Regimen For Biliary Tract Cancer
September 06, 2022
Via
Benzinga
AstraZeneca Scores Its First Global Approval For Antibody Evusheld As COVID-19 Treatment
August 30, 2022
Via
Benzinga
Valneva Posts Additional Encouraging Data From COVID-19 Booster Trial
August 29, 2022
Via
Benzinga
AstraZeneca Touts Positive Farxiga Data, Seeks Label Expansion In Heart Failure
August 29, 2022
AstraZeneca Plc (NASDAQ: AZN) laid out the details of the Farxiga's performance in another heart failure patient population at the European Society of Cardiology Congress.
Via
Benzinga
Back-To-Back Three Japanese Approvals For AstraZeneca's Rare Disease Treatments
August 25, 2022
Via
Benzinga
AstraZeneca's CEO Says There Are No COVID Regrets, Looks For Oncology Acquisitions
August 24, 2022
In a Reuters report, AstraZeneca Plc's (NASDAQ:
Via
Benzinga
AstraZeneca Slaps Lawsuit Against Former Employee As He Moves To Close Rival: Report
August 17, 2022
Via
Benzinga
UK Government Will Not Buy More AstraZeneca's COVID-19 Treatment
August 16, 2022
Via
Benzinga
AstraZeneca-Merck's Prostate Cancer Drug Under FDA Priority Review For Expanded Use
August 16, 2022
Via
Benzinga
AstraZeneca-Daiichi's Flagship Breast Cancer Drug Improves Survival In Late-Stage Study
August 15, 2022
Via
Benzinga
Daiichi-AstraZeneca's Flagship Cancer Drug Scores FDA Approval For Lung Cancer Harboring HER2 Mutation
August 12, 2022
Via
Benzinga
AstraZeneca's Dato-DXd-Based Combo Therapies Show Promising Activity In Lung Cancer Patients
August 09, 2022
Via
Benzinga
AstraZeneca's Tagrisso Doublet Therapy Shows 49% Response Rate In Lung Cancer Setting
August 08, 2022
Via
Benzinga
Pieris Stops Work On Cancer Med, Tested In Combo With Eli Lilly Drugs
August 04, 2022
Via
Benzinga
AstraZeneca Cuts Innate-Partnered Phase 3 Trial In Head & Neck Cancer
August 01, 2022
Via
Benzinga
AstraZeneca Drops Moderna-Partnered, Phase 2 Heart Disease Drug Candidate
July 29, 2022
AstraZeneca Plc (NASDAQ: AZN) has removed a Moderna Inc (NASDAQ: MRNA)-partnered cardiovascular disease candidate from its phase 2 pipeline.
Via
Benzinga
AstraZeneca Q2 Highlights: Profits Fall, COVID-19 Vaccine Sales Dip, Lifts Annual Sales Guidance
July 29, 2022
Via
Benzinga
Europe's CHMP Recommends Approving AstraZeneca's Asthma, Neuromuscular Disorder Treatments
July 25, 2022
Via
Benzinga
Merck & AstraZeneca Partnered Lynparza Fails In Late-Stage Colorectal Cancer Study
July 19, 2022
Via
Benzinga
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings
July 19, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
AstraZeneca's Enhertu Wins European Approval For Pretreated Breast Cancer Setting
July 19, 2022
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.